HEXO Reports Q1’23 Financial Results

Published: December 16, 2022

HEXO Reports Q1’23 Financial Results

HEXO Corp., a leading producer of high-quality cannabis products, today reported its financial results for the first quarter (Q1 ’23). All currency amounts are stated in Canadian dollars unless otherwise noted.

“The first quarter of 2023 has been one of incredible progress for HEXO,” said Charlie Bowman, President and CEO of HEXO. “We’re now seeing the results of the strategic realignment we executed over the past two quarters and have successfully reset the Company for long-term success. Our laser focus on tackling the balance sheet, pulling back on those unprofitable products where our strengths in premium cultivation were not being leveraged and expanding further into opportunities where we know we can win, is paying off across the business.”

“Over the past six months, we’ve made favourable amendments to our debt structure and have paid off, in early December, more than $40 million of legacy debt. We’ve reduced our general and administrative and selling, marketing and promotion expenses by $18 million and have substantially lowered our overhead costs,” noted Julius Ivancsits, Chief Financial Officer of HEXO. “We’ve increased our gross profit before fair value adjustments by approximately $41 million over the previous quarter and have significantly decreased our inventory levels. We’ve also eliminated unprofitable sales, redeploying those resources into profitable business segments.”

“These actions have paved the way for profitable growth and we’re now building positions of strength in those areas where HEXO excels,” continued Mr. Bowman. “We’ve redesigned and upgraded our Masson grow facility, have signed new cultivation agreements, including the partnerships with Entourage and Tilray, and have announced the launch of a top shelf, premium brand, T 2.0, into the Canadian marketplace. Our Redecan brand achieved record sales in the quarter and we’ve since increased our output of Redees pre-rolls by more than 300% with no capital investment, enabling us to expand our portfolio to meet consumer demand across Canada for these products.”

Significant Financial Results

  • The Company recorded an Adjusted EBITDA loss of $(0.6) million during the three months ended October 31, 2022 (“Q1’23”), an improvement of $6.9 million from the fourth quarter of FY22 (“Q4’22”), and an improvement of $11 million from the first quarter of FY22 (“Q1’22”).
  • The Company recorded a total net loss before tax of $(57.1) million in Q1’23, an improvement as compared to net losses before tax of $(106.2) million in Q4’22 and $(117.4) million in Q1’22, respectively.
  • Q1’23 net revenues were $35.8 million, a decrease of 29% comparatively to $50.2 million in Q1’22 and a decrease of 16% compared to $42.5 million net revenue in Q4’22.
  • Total operating expenses were significantly reduced by 69% or $50.7 million quarter over quarter and 81% or $100 million as compared to Q1’22.
  • Operating cash outflows were reduced by $27.7 million or 49% when compared to Q1’22.

Key Financial Results
(in thousands of Canadian dollars)

 For the three months ended October 31, 2022 July 31, 2022 October 31, 2021
$ $ $
Revenue from sale of goods 51,815 60,227 69,497
Excise taxes (17,340 ) (17,910 ) (19,535 )
Net revenue from sale of goods 34,475 42,317 49,962
Service and ancillary revenue 1,296 177 226
Net revenue 35,771 42,494 50,188
Cost of goods sold (35,563 ) (83,432 ) (82,985 )
Gross loss before fair value adjustments 208 (40,938 ) (32,797 )
Fair value component in inventory sold (19,966 ) (11,826 ) (12,760 )
Unrealized gain on changes in fair value of biological assets 2,403 16,901 13,581
Gross (loss)/profit (17,355 ) (35,863 ) (31,976 )
Operating expenses (23,164 ) (73,903 ) (123,133 )
Loss from operations (40,519 ) (109,766 ) (155,109 )
Finance income (expense), net (1,917 ) 16,664 (4,531 )
Non-operating income (expense), net (14,632 ) (13,072 ) 42,213
Loss before tax (57,068 ) (106,174 ) (117,427 )
Current and deferred tax recovery 813 5,787 155
Other comprehensive income 4,201 (1,980 ) 364
Total net loss and comprehensive loss (52,054 ) (102,367 ) (116,908 )

Net Revenue:

  • Q1’23 total net revenue decreased by 16% compared to Q4’22. The decline was in part, attributable to the timing of revenue recognition as certain shipments failed to reach their destination due to severe weather towards the period end. Other challenges were faced, leading to shortages of desired products, and short filling purchase orders as the Company continues to implement its revised demand planning process.
  • Q1’23 total net revenue decreased by 29% compared to Q1’22. The decline in revenue is attributable to proactive decisions to realign the HEXO brand’s profitable product and cull products that were no longer meeting profitability standards.

Cost of Goods Sold & Adjusted Gross Margin:

The following table summarizes and reconciles the Company’s gross profit line items per IFRS to the Company’s selected non-IFRS financial measures adjusted cost of sales, gross profit/margin before adjustments and gross profit before fair value adjustments. Refer to the ‘Non-IFRS Measures’ section below for definitions.

 For the three months ended (in thousands of Canadian dollars) October 31, July 31, October 31,
2022 2022 2021
$ $ $
Net revenue from the sale of goods 34,475 42,317 49,962
Adjusted cost of sales (26,248 ) (37,281 ) (37,270 )
Gross profit before adjustments 8,227 5,036 12,692
Gross margin before adjustments 24% 12% 25%
Write off of biological assets and destruction costs (980 )
Write off of inventory (4,400 ) (6,768 ) (615 )
Write (down)/up of inventory to net realizable value (4,915 ) (36,331 ) (36,197 )
Crystallization1 of fair value on business combination accounting (3,052 ) (7,923 )
Gross (loss)/profit before fair value adjustments (1,088 ) (41,115 ) (33,023 )
Realized fair value amounts on inventory sold (19,966 ) (11,826 ) (12,760 )
Unrealized gain on changes in fair value of biological assets 2,403 16,901 13,581
Gross (loss)/profit (18,651 ) (36,040 ) (32,202 )
1 This is a supplementary financial measure. See section “Key Operating Performance Indicators” of the MD&A for additional details.
  • Total gross margin before adjustments has been improved to 24% from 12% quarter over quarter, in part as a result of certain inefficiencies recognized in Q4’22 due to the consolidation of operations and facility closure.
  • Cost of goods sold improved to $35.6 million in Q1’23 relative to $83.0 million recognized in Q1’22 and $83.4 million in Q4’22. Driving the improvements were the significant reductions to inventory impairments and net realizable value adjustments as management continues to focus on aligning cultivation to demand and mitigate the risk of aged out and unsellable stock. Additionally, the crystallization of fair value from business combinations was fully realized in Q4’22 and therefore did not factor into Q1’23.
  • Unrealized gains on changes in fair value of biological assets has significantly declined primarily as the result of fewer plants on hand. The Company harvested the bulk of its outdoor grow cultivated over the summer months during the period and relative to Q1’22 the Company has reduced its total grow facilities through the consolidation and reorganization of its operational footprint.

Operating Expenses

For the three months ended (in thousands of Canadian dollars) October 31, July 31, October 31,
2022 2022 2021
$ $ $
General and administration (“G&A”) 10,466 12,586 22,484
Selling, Marketing and promotion (“S,M&P”) 4,106 4,975 6,223
Share-based compensation 959 786 3,824
Research and development (“R&D”) 322 231 967
Depreciation of property, plant and equipment 784 2,652 2,057
Amortization of intangible assets 2,871 3,338 8,158
Restructuring costs 1,062 3,788 3,989
Impairment of property, plant and equipment (611 ) 7,899 23,803
Recognition of onerous contract 1,000
Impairment of Investment in joint ventures and associates 30,835 26,925
Loss/(gain) on disposal of property, plant and equipment (510 ) 396 329
Acquisition transaction and integration costs 3,715 5,417 24,374
Total 23,164 73,903 123,133

General and Administration Expenses by Nature

For the three months ended (in thousands of Canadian dollars) October 31, October 31,
2022 2021
$ $
Salaries and benefits 2,895 10,191
General and administrative 3,743 5,901
Professional fees 3,375 5,848
Consulting 453 544
  Total 10,466 22,484

Operating Expenses:

  • Operating expenses in Q1’23 totaled $23.2 million, a $50.7 million improvement from Q4’22. Excluding the impact of impairments and restructuring activities, operating expenses have decreased $17.2 million as a result of the Company’s cost saving measures and reduced sunk costs and overhead charges from the Zenabis deconsolidation in Q4’22.
  • Operating expenses in Q1’23 decreased by $100 million or 81% comparatively from Q1’22. Driving the improvements was the significant reduction in acquisition, transaction and integration charges from the Company’s M&A activity in Q1’22 as well as the reduction to non-cash impairment losses. However, the Company’s G&A, S,M&P and R&D operating expenses have decreased $14.8 million relative to Q1’22 due to general cost saving measures, realized efficiencies, reorganization of the business structure and the restructuring of these consolidated operations.

Other income and losses

For the three months ended (in thousands of Canadian dollars) October 31,
July 31,
October 31,
$ $ $
Interest and financing expenses (2,467 ) (4,371 ) (5,305 )
Interest income 550 501 774
Net gain on extinguishment of debt 20,534
Finance income (expense), net (1,917 ) 16,664 (4,531 )
Revaluation of warrant liabilities 2 1,791 27,467
Share of loss from investment in associate and joint ventures (2,398 ) (2,482 ) (2,149 )
Fair value loss on senior secured convertible note (6,270 ) (52,690 ) 11,670
Loss on investments 140 (140 ) (279 )
Net gain on loss of control of subsidiary                         – 25,009
Foreign exchange gain/(loss) (9,023 ) (1,058 ) 5,504
Other income 2,917 16,498
Non-operating income (expense), net (14,632 ) (13,072 ) 42,213
  • Total non-operating expenses and finance expenses decreased $20.1 million quarter over quarter. The extinguishment of debt, the fully amortization of the day 1 loss associated with previous senior secured note and loss of control of the Zenabis Group were Q4’22 specific events which had no impact on the current period. Other income has decreased sequentially due to the net gain realized on the Belleville lease termination, another Q4’22 specific event. Unrealized foreign exchange losses were the result of unfavorable CAD/USD rates applied to the Company’s USD denominated debt.
  • Total non-operating expenses and finance expenses decreased $54.2 million relative to Q1’22. Driving this change were the reduced volatility in the revaluation of warrants, a favorable fair valuation gain on the previous senior secured convertible note, and foreign exchange gains due to favorable CAD/USD rates.

Reconciliation of Adjusted Earnings before interests, taxes, depreciation and amortization (“EBITDA”) to Total net loss before tax(in thousands of Canadian dollars)

Q1’23 Q4’22 Q1’22
$ $ $
Total net loss before tax (57,068 ) (106,174 ) (117,427 )
   Finance expense (income), net 1,917 3,870 4,531
Depreciation (cost of sales) 4,773 5,112 4,969
Depreciation (operating expenses) 784 2,652 2,057
   Amortization (operating expenses) 2,871 3,338 8,158
EBITDA (46,723 ) (91,202 ) (97,712 )
Investment (gains) losses 17,549 9,036 (42,213 )
Non-cash fair value adjustments 17,563 (2,023 ) 7,102
Non-recurring expenses 4,777 9,205 28,363
Other non-cash items 6,236 67,517 92,884
Adjusted EBITDA  (598 ) (7,467 ) (11,576 )

Select Balance Sheet Metrics
(in thousands of Canadian dollars)

As at October 31,
July 31,
$ $
Cash & cash equivalents 78,484 83,238
Restricted funds 2,180 32,224
Biological assets & inventory 57,530 82,315
Other current assets 2 74,498 73,870
Accounts payable & accrued liabilities 39,296 72,581
Senior secured convertible note & convertible debenture 262,326 248,680
Adjusted working capital1 88,730 123,730
Property, plant & equipment 280,883 285,866
Assets held for sale 5,531 5,121
Total Assets 616,964 680,949
Total Liabilities 353,104 367,257
Shareholders’ equity 263,860 313,692
1 Defined as the Company’s current assets less current liabilities net of the senior secured convertible note. The note is classified as a current liability as the lender possess the ability to unilaterally convert the note to equity and therefore does not represent a cash-based liability to the Company within one-year of October 31, 2022. Working capital is utilized as a key metric for management in assessing the Company’s ability to meet its future obligations.
2 Total current assets less cash and cash equivalents, restricted funds, biological and inventory.

Liquidity Risk
The Company’s ability to continue as a going concern is dependent upon its ability in the future to achieve profitable operations and, in the meantime, to obtain the necessary financing to meet its obligations and comply with the related covenants, and to repay its liabilities when they become due. External financing, predominantly by the issuance of equity to the public or debt, will be sought to finance the operations of the Company.

On October 31, 2022, the Company had cash and cash equivalents of $78.5 million ($83.2 million at July 31, 2022). Subsequent to Q1’23 on December 5, 2022, the Company’s 8% convertible debenture matured and a total of $40.7 million was repaid in respect of the outstanding principal and unpaid interest. Under the terms of the senior secured convertible note, the Company is subject to a minimum liquidity covenant of US$20 million.

Thus, there remains a risk that the Company’s cost saving initiatives may not yield sufficient operating cash flow to meet its financial covenant requirements, and as such, these circumstances create material uncertainties that lend substantial doubt as to the ability of the Company to meet its obligations as they come due and, accordingly, the appropriateness of the use of accounting principles applicable to a going concern.

About HEXO Corp.
HEXO is an award-winning licensed producer of innovative products for the global cannabis market. HEXO serves the Canadian recreational market with a brand portfolio including HEXO, Redecan, UP Cannabis, Original Stash, 48North, Trail Mix, Bake Sale and Latitude brands, and the medical market in Canada. With the completion of HEXO’s acquisitions of Redecan and 48North, HEXO is a leading cannabis products company in Canada by recreational market share. For more information, please visit hexocorp.com.